Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 3/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877678 | 1.00 | PTGDR2 (0.34) | PTGDR2USP14RORCENPP3KDM4E | |
| SCHEMBL17877859 | 0.96 | PTGDR2 (0.36) | PTGDR2USP14RORCENPP3KDM4E | |
| SCHEMBL17877799 | 0.96 | PTGDR2 (0.36) | PTGDR2USP14RORCENPP3KDM4E | |
| SCHEMBL17877796 | 0.96 | PTGDR2 (0.36) | PTGDR2USP14RORCENPP3KDM4E | |
| SCHEMBL17877798 | 0.96 | PTGDR2 (0.36) | PTGDR2USP14RORCENPP3KDM4E | |
| SCHEMBL17877790 | 0.91 | PTGDR2 (0.33) | PTGDR2 | |
| SCHEMBL17877800 | 0.90 | USP14 (0.37) | PTGDR2USP14ALKLRRK2G6PD | |
| SCHEMBL17877841 | 0.87 | PTGDR2 (0.34) | PTGDR2USP14G6PD | |
| SCHEMBL17877765 | 0.87 | TNKS (0.33) | — | |
| SCHEMBL17877783 | 0.87 | TNKS (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | PTGDR2 2045/4885USP14 3083/4885RORC 1669/4885 |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | PTGDR2 2045/4885USP14 3083/4885RORC 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.